July, 21 2022 Successful completion of Series A: EUR 10 million investment for MedTech startup PreciPoint

Pre­ci­Point Group GmbH has suc­cess­fully closed its Series A financ­ing round of EUR 10 mil­lion. Exist­ing investors, includ­ing bm‑t beteili­gungs­man­age­ment thürin­gen gmbh (bm|t), and a new fam­ily office invested in the Ger­man MedTech startup. This financ­ing round will advance the inter­na­tional com­mer­cial­iza­tion of the company´s first IVD med­ical prod­uct, mar­ket entry in the USA as well as fur­ther tech­no­log­i­cal devel­op­ment of addi­tional inno­v­a­tive solutions.

In 2022, Pre­ci­Point will com­mer­cially launch the iO:M8 ROSE, a glob­ally unique solu­tion for the dig­i­ti­za­tion of intra­op­er­a­tive micro­scopic assess­ments dur­ing can­cer surg­eries. These exam­i­na­tions, dur­ing which pathol­o­gists deter­mine whether suf­fi­cient mate­r­ial has been removed from the patient’s body and whether the mar­gins are free of can­cer cells, are tra­di­tion­ally per­formed by spe­cial­ists being bound to loca­tion and time using clas­sic light micro­scopes for imag­ing. PreciPoint’s solu­tions enable entirely new ways of work­ing, allow­ing sig­nif­i­cant cost sav­ings and, most impor­tantly, bet­ter patient care.

Pre­ci­Point spe­cial­izes in the dig­i­ti­za­tion of microscopy and lab­o­ra­tory work­flows. The com­pany offers solu­tions for appli­ca­tions in med­i­cine, research, and edu­ca­tion and its devices are used in many lab­o­ra­to­ries world­wide. It is cen­tral to PreciPoint’s phi­los­o­phy to develop prod­ucts together with users. Thus, the com­pany works with many respected pathol­o­gists in Ger­many to design prod­ucts that meet the high­est stan­dards while being quick and easy to use. This includes a focus on the devel­op­ment of tech­nolo­gies for Label-Free Diag­nos­tics, where sam­ples can be viewed entirely with­out expen­sive and time-con­sum­ing sam­ple prepa­ra­tion, as well as the devel­op­ment of prod­uct solu­tions for high-speed appli­ca­tions to help meet the increas­ing demand in pathol­ogy labs.

Excel­lent prospects that also con­vinced the investors: “Since our seed invest­ment in 2019, the team around the two co-founders and man­ag­ing direc­tors Nico­las Weiss and Dominik Ger­ber has made enor­mous progress. Renowned dis­tri­b­u­tion part­ners could be acquired, new prod­ucts could be devel­oped and suc­cess­fully placed on the mar­ket. At the same time, the pre­req­ui­sites were cre­ated to quickly scale the com­pany. We firmly believe that Pre­ci­Point, as a ISO13485 cer­ti­fied med­ical device com­pany, will be able to suc­cess­fully posi­tion its prod­uct port­fo­lio on the Euro­pean and Amer­i­can mar­kets,” said Ste­fan Jahn, Senior Invest­ment Man­ager at bm|t.

About PreciPoint

Pre­ci­Point spe­cial­izes in the devel­op­ment, pro­duc­tion, and mar­ket­ing of inno­v­a­tive dig­i­ti­za­tion solu­tions and pho­ton­ics sys­tems in the field of microscopy. Already offered on the mar­ket are the microscopy solu­tions M8, O8 as well as FRITZ. All devices are fully motor­ized trans­mit­ted light micro­scopes users con­trol via soft­ware. The solu­tions work dig­i­tally, do not require an eye­piece, and pro­duce high-res­o­lu­tion images of the sam­ples, which can eas­ily be stored dig­i­tally.  The micro­scopes impress with easy and intu­itive user inter­faces. Fur­ther­more, the devices can be equipped with a remote func­tion so that they can also be accessed from any loca­tion. In addi­tion to hard­ware prod­ucts, the com­pany offers ver­sa­tile soft­ware appli­ca­tions with which the images can be visu­al­ized, processed, and ana­lyzed. The vir­tual microscopy plat­form Pre­ci­Cloud enables new work­ing mod­els between experts, researchers, and stu­dents. PreciPoint’s cus­tomer base already includes many well-known users world­wide. Based in Freis­ing, Ger­many, Pre­ci­Point is an ISO 13485 cer­ti­fied med­ical device com­pany and one of the Top Star­tups in Ger­many. The com­pany has won var­i­ous awards, includ­ing 3rd place as Top Inno­va­tor 2022, in which Pre­ci­Point pre­vailed as a par­tic­u­larly inno­v­a­tive com­pany against almost 450 com­pa­nies, and the award as Top Startup Employer in the health­care sector.


About bmt beteiligungsmanagement thüringen gmbh (bm|t)

Erfurt-based, bm|t is the first address for invest­ments in Thuringia, Ger­many. bm|t cur­rently man­ages nine funds with a total vol­ume of over EUR 350 mil­lion and invests in inno­v­a­tive com­pa­nies with strong growth poten­tial across all sec­tors and all phases of the cor­po­rate lifecycle.